Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2770560 | 0.95 | GNAI3 (0.42) | CES2GNAI3GNAO1GNAI1DNM1 | |
| SCHEMBL2935191 | 0.92 | CES2 (0.52) | CES2 | |
| SCHEMBL8917791 | 0.92 | CES2 (0.52) | CES2 | |
| SCHEMBL7663036 | 0.92 | CES2 (0.52) | CES2 | |
| SCHEMBL4958852 | 0.92 | CES2 (0.52) | CES2 | |
| SCHEMBL693122 | 0.92 | CES2 (0.52) | CES2 | |
| SCHEMBL11540653 | 0.92 | CES2 (0.52) | CES2 | |
| SCHEMBL2304845 | 0.92 | CES2 (0.52) | CES2 | |
| SCHEMBL9119248 | 0.92 | CES2 (0.52) | CES2 | |
| SCHEMBL5802863 | 0.92 | CES2 (0.52) | CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2525809-B1 | GLUCAGON-GLP1 DUAL AGONISTS FOR USE IN THE TREATMENT OF CARDIAC CONDITIONS | ZEALAND PHARMA AS (DK) | 2016-08-03 | — | — | EP | claimed |
| US-20160120951-A1 | ACYLATED GLUCAGON ANALOGUES | ZEALAND PHARMA A/S (DK) | 2016-05-05 | — | — | US | claimed |
| US-20160000883-A1 | COMBINATION OF ACYLATED GLUCAGON ANALOGUES WITH INSULIN ANALOGUES | ZEALAND PHARMA A/S (DK) | 2016-01-07 | — | — | US | claimed |
| EP-2454282-B1 | ACYLATED GLUCAGON ANALOGUES | ZEALAND PHARMA AS (DK) | 2015-03-04 | — | — | EP | claimed |
| US-20140011733-A1 | COMBINATION OF ACYLATED GLUCAGON ANALOGUES WITH INSULIN ANALOGUES | ZEALAND PHARMA A/S (DK) | 2014-01-09 | — | — | US | claimed |
| EP-2665487-A1 | COMBINATION OF ACYLATED GLUCAGON ANALOGUES WITH INSULIN ANALOGUES | Zealand Pharma A/S (DK) | 2013-11-27 | — | — | EP | claimed |
| US-20130157953-A1 | TREATMENT OF CARDIAC CONDITIONS | ZEALAND PHARMA A/S (DK) | 2013-06-20 | — | — | US | claimed |
| WO-2012098462-A1 | COMBINATION OF ACYLATED GLUCAGON ANALOGUES WITH INSULIN ANALOGUES | ZEALAND PHARMA A/S (DK) | 2012-07-26 | — | — | WO | claimed |
| US-20120178670-A1 | ACYLATED GLUCAGON ANALOGUES | ZEALAND PHARMA A/S (DK) | 2012-07-12 | — | — | US | claimed |
| EP-2454282-A1 | ACYLATED GLUCAGON ANALOGUES | Zealand Pharma A/S (DK) | 2012-05-23 | — | — | EP | claimed |
| WO-2011088837-A1 | TREATMENT OF CARDIAC CONDITIONS | ZEALAND PHARMA A/S (DK) | 2011-07-28 | — | — | WO | claimed |
| WO-2011006497-A1 | ACYLATED GLUCAGON ANALOGUES | ZEALAND PHARMA A/S (DK) | 2011-01-20 | — | — | WO | claimed |
| EP-2585482-B1 | GLUCAGON ANALOGUES | ZEALAND PHARMA AS (DK) | 2019-03-27 | — | — | EP | disclosed |
| US-20190076506-A1 | ACYLATED GLUCAGON ANALOGUES | ZEALAND PHARMA A/S (DK) | 2019-03-14 | — | — | US | disclosed |
| US-10004786-B2 | Acylated glucagon analogues | ZEALAND PHARMA A/S (DK) | 2018-06-26 | — | — | US | disclosed |
| US-20160120951-A1 | ACYLATED GLUCAGON ANALOGUES | ZEALAND PHARMA A/S (DK) | 2016-05-05 | — | — | US | disclosed |
| US-20120178670-A1 | ACYLATED GLUCAGON ANALOGUES | ZEALAND PHARMA A/S (DK) | 2012-07-12 | — | — | US | disclosed |
| EP-2454282-A1 | ACYLATED GLUCAGON ANALOGUES | Zealand Pharma A/S (DK) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011160633-A1 | GLUCAGON ANALOGUES | ZEALAND PHARMA A/S (DK) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011006497-A1 | ACYLATED GLUCAGON ANALOGUES | ZEALAND PHARMA A/S (DK) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160120951-A1 | ACYLATED GLUCAGON ANALOGUES | GLP1R, GCGR, GIPR | CES2 3033/4885GNAI3 300/4885GNAO1 450/4885 |
| US-10004786-B2 | Acylated glucagon analogues | GLP1R, GCGR, GIPR | CES2 3035/4885GNAI3 305/4885GNAO1 448/4885 |
| US-20140011733-A1 | COMBINATION OF ACYLATED GLUCAGON ANALOGUES WITH INSULIN ANALOGUES | IAPP, GLP1R, GCG | CES2 2343/4885GNAI3 225/4885GNAO1 1047/4885 |
| US-20190076506-A1 | ACYLATED GLUCAGON ANALOGUES | GLP1R, GCGR, GIPR | CES2 3033/4885GNAI3 300/4885GNAO1 450/4885 |
| US-20160000883-A1 | COMBINATION OF ACYLATED GLUCAGON ANALOGUES WITH INSULIN ANALOGUES | IAPP, GLP1R, GCG | CES2 2343/4885GNAI3 225/4885GNAO1 1047/4885 |
| US-20120178670-A1 | ACYLATED GLUCAGON ANALOGUES | GLP1R, GCGR, GIPR | CES2 3033/4885GNAI3 300/4885GNAO1 450/4885 |
| US-20130157953-A1 | TREATMENT OF CARDIAC CONDITIONS | GLP1R, GCGR, TNNT2 | CES2 2931/4885GNAI3 258/4885GNAO1 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.